Davenport & Co’s Novavax NVAX Stock Holding History

Davenport & Co’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,500	Closed	-$28K	–	692
2019 Q1	$28K	Buy	2,500 +2,000	+400%	+$63.1K	﹤0.01%	652
2018 Q4	$18K	Hold	500	–	–	﹤0.01%	629
2018 Q3	$19K	Buy	+500	New	+$14.1K	﹤0.01%	676

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Davenport & Co's NVAX Position: Q2 2019 in Review

Davenport & Co sold out of Novavax (NVAX) in Q2 2019, closing a stake of 2,500 shares — an estimated $28K sold.

Davenport & Co first reported a position in NVAX in Q3 2018 and held it in 3 quarters. The position peaked at $28K in Q1 2019. 81 funds tracked by Wall St. Rank hold NVAX as of Q2 2019.

Davenport & Co reported no remaining Novavax position as of Q2 2019 after selling out during the quarter.
Davenport & Co sold 2,500 Novavax shares in Q2 2019, an estimated $28K.
Davenport & Co first reported a position in Novavax in Q3 2018 and held it in 3 quarters.
Davenport & Co's Novavax position peaked at $28K in Q1 2019.
81 funds tracked by Wall St. Rank held Novavax as of Q2 2019.

Based on Davenport & Co's 13F filing for Q2 2019, filed 10 Jul 2019.